Generation of stem cell-derived β-cells from patients with type 1 diabetes
Summary
We recently reported the scalable in vitro production of functional stem cell-derived β-cells (SC-β cells). Here we extend this approach to generate the first SC-β cells from type 1 diabetic patients (T1D). β-cells are destroyed during T1D disease progression, making it difficult to extensively study them in the past. These T1D SC-β cells express β-cell markers, respond to glucose both in vitro and in vivo, prevent alloxan-induced diabetes in mice and respond to anti-diabetic drugs. Furthermore, we use an in vitro disease model to demonstrate the cells respond to different forms of β-cell stress. Using these assays, we find no major differences in T1D SC-β cells compared with SC-β cells derived from non-diabetic patients. These results show that T1D SC-β cells could potentially be used for the treatment of diabetes, drug screening and the study of β-cell biology.
| Authors | Millman JR, Xie C, Van Dervort A, Gürtler M, Pagliuca FW, Melton DA |
|---|---|
| Journal | Nature communications |
| Publication Date | 2016 May 10;7:11463 |
| PubMed | 27163171 |
| PubMed Central | PMC4866045 |
| DOI | 10.1038/ncomms11463 |